Thermo Fisher Scientific Inc.

AI increases the number of drug candidates and scientific hypotheses, leading to greater demand for physical lab testing. This is likely to trigger a new investment cycle for lab equipment and services, from which Thermo Fisher can directly benefit. Rising demand for analytical and testing capacity is driving the company’s growth story in the AI era. » Więcej na finanzen.net

Thermo Fisher Scientific benefits from structural trends in biopharmaceutical research and is pursuing a strategic realignment to strengthen its diversified business model. The company supplies laboratory equipment, analytical instruments, reagents and diagnostic solutions and views demographic drivers as growth catalysts. Results for the third quarter, to be released on October 21, are regarded as an important indicator of margin development. » Więcej na finanzen.net

Around 950 AI agents analyzed over 200,000 reverse transcriptases within 21 hours and identified thousands of new candidate systems, including a previously uncharacterized enzyme system with CRISPR-like repeats. The results required experimental confirmation in the wet lab, increasing the need for automated laboratory workflows. Thermo Fisher and NVIDIA are therefore jointly expanding the infrastructure so AI agents can plan experiments, control instruments, and evaluate results in increasingly autonomous labs. » Więcej na finanzen.net

Fenimore Asset Management initiated a position in Thermo Fisher Scientific, describing it as a leading 'picks-and-shovels' provider to the life sciences industry with durable recurring revenue. The firm cited post-COVID normalization and pharma funding concerns as reasons for recent share weakness but expects Thermo Fisher to resume growth as industry trends remain strong. Thermo Fisher closed at $658.32 on Sept. 17, with a one-year gain of 37.13% and a market capitalization of $242.56 billion. » Więcej na finance.yahoo.com

Anthropic has built a wet lab and for the first time connects Claude to laboratory robots, moving AI drug discovery from the screen into the physical experimental world. Claude can already design protein binders and showed high success rates in tests. The development boosts Thermo Fisher’s growth prospects as a supplier and potential winner of the biotechnology‑AI revolution. » Więcej na finanzen.net